SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Public ClinicalTrials.gov record NCT04762160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
SYMPHONY-II: A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1 anti-CD20-based regimen was used.
Study identification
- NCT ID
- NCT04762160
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 5 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 14, 2020
- Primary completion
- Mar 21, 2022
- Completion
- Mar 21, 2022
- Last update posted
- Mar 24, 2024
2020 – 2022
United States locations
- U.S. sites
- 20
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama Oncology | Birmingham | Alabama | 35223 | — |
| Compassionate Cancer Care | Fountain Valley | California | 92708 | — |
| USOR/Rocky Mountain Cancer Centers | Boulder | Colorado | 80303 | — |
| USOR/ Illinois Cancer Specialists | Niles | Illinois | 60714 | — |
| XCancer/ Northwest Oncology & Hematology | Rolling Meadows | Illinois | 60008 | — |
| Revive/Oakland Medical Group | Farmington Hills | Michigan | 48336 | — |
| Revive/Hematology Oncology Associates of Rockland | Sterling Heights | Michigan | 48314 | — |
| USOR/ NY Oncology Hematology | Albany | New York | 12206 | — |
| East Carolina University | Greenville | North Carolina | 27858 | — |
| USOR/ Oncology & Hematology Care Clinical Trials | Cincinnati | Ohio | 45236 | — |
| XCancer/Dayton Physicians Network | Kettering | Ohio | 45409 | — |
| XCancer/Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| USOR/ Texas Oncology | Austin | Texas | 78705 | — |
| USOR/Texas Oncology | Dallas | Texas | 75230 | — |
| USOR/ Texas Oncology | San Antonio | Texas | 78240 | — |
| USOR/ Texas Oncology | Tyler | Texas | 75702 | — |
| USOR/Texas Oncology | Weslaco | Texas | 78596 | — |
| USOR/Virginia Cancer Specialists | Gainesville | Virginia | 20155 | — |
| USOR/Oncology & Hematology Associates of Southwest Virginia | Roanoke | Virginia | 24014 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04762160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2024 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04762160 live on ClinicalTrials.gov.